Development of a fluorogenic small substrate for dipeptidyl peptidase-4

被引：4

作者：

Ogawa, Futa ^{[1
]}

Takeda, Masanori ^{[1
]}

Miyanaga, Kanae ^{[2
]}

Tani, Keita ^{[2
]}

Yamazawa, Ryuji ^{[1
]}

Ito, Kiyoshi ^{[1
]}

Tarui, Atsushi ^{[1
]}

Sato, Kazuyuki ^{[1
]}

Omote, Masaaki ^{[1
]}

机构：

[1] Setsunan Univ, Fac Pharmaceut Sci, 45-1 Nagaotoge Cho, Hirakata, Osaka 5730101, Japan

[2] Osaka Kyoiku Univ, Div Nat Sci, Osaka 5828582, Japan

来源：

BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY | 2017年 / 13卷

关键词：

dipeptidyl peptidase-4; fluorogenic substrate; fluorometry; small fluorescent molecule; SOLID-STATE; FLUORESCENT-PROBE; IN-VIVO; CELLS; DESIGN; VIOLET; TUMOR; IV;

D O I：

10.3762/bjoc.13.267

中图分类号：

O62 [有机化学];

学科分类号：

070303 ; 081704 ;

摘要：

A series of aniline and m-phenylenediamine derivatives with electron-withdrawing 3,3,3-trifluoropropenyl substituents were synthesized as small and chemically stable fluorescent organic compounds. Their fluorescence performances were evaluated by converting 2,4-disubstituted aniline 1 to the non-fluorescent dipeptide analogue H-Gly-Pro-1 for the use as a fluorogenic substrate for dipeptidyl peptidase-4 (DPP-4). The progress of the enzymatic hydrolysis of H-Gly-Pro-1 with DPP-4 was monitored by fluorometric determination of 1 released into the reaction medium. The results suggest that 1 could be used as fluorophore in OFF-ON-type fluorogenic probes.

引用

页码：2690 / 2697

页数：8

共 50 条

[11] Cardiovascular effects of dipeptidyl peptidase-4 inhibitors
Papagianni, M.
Tziomalos, K.
HIPPOKRATIA, 2015, 19 (03) : 195 - 199
[12] The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
Kim, Na-Hyung
Yu, Taeyang
Lee, Dae Ho
BIOMED RESEARCH INTERNATIONAL, 2014, 2014
[13] Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
Shi, Sen
Koya, Daisuke
Kanasaki, Keizo
FIBROGENESIS & TISSUE REPAIR, 2016, 9
[14] Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review
Richard, Kathleen R.
Shelburne, Jamie S.
Kirk, Julienne K.
CLINICAL THERAPEUTICS, 2011, 33 (11) : 1609 - 1629
[15] Dipeptidyl peptidase-4 inhibitors and cardiovascular safety
Davis, Timothy M. E.
MEDICAL JOURNAL OF AUSTRALIA, 2014, 200 (08) : 450 - 451
[16] Pharmacology of Dipeptidyl Peptidase-4 InhibitorsSimilarities and Differences
Roberta Baetta
Alberto Corsini
Drugs, 2011, 71 : 1441 - 1467
[17] Nonglycemic effects of dipeptidyl peptidase-4 inhibitors
Ametov, A. S.
Kamynina, L. L.
TERAPEVTICHESKII ARKHIV, 2013, 85 (01) : 98 - 102
[18] Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
Hong, Sangmo
Jung, Chang Hee
Han, Song
Park, Cheol-Young
DIABETES & METABOLISM JOURNAL, 2022, 46 (01) : 63 - +
[19] Development of a Scalable Synthesis of Dipeptidyl Peptidase-4 Inhibitor ABT-279
McDermott, Todd S.
Bhagavatula, Lakshmi
Borchardt, Thomas B.
Engstrom, Kenneth M.
Gandarilla, Jorge
Kotecki, Brian J.
Kruger, Albert W.
Rozema, Michael J.
Sheikh, Ahmad Y.
Wagaw, Seble H.
Wittenberger, Steven J.
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2009, 13 (06) : 1145 - 1155
[20] Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?
Saisho, Y.
Itoh, H.
DIABETIC MEDICINE, 2013, 30 (04) : e149 - e150

← 1 2 3 4 5 →